Physician profile
Omar A Aref
NPI 1235106675
$6,850.54
in general payments reported to CMS, 2019-2025
37 companies · $808 in 2025
The $808 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $918 · 2021: $988 · 2022: $1,012 · 2023: $1,188 · 2024: $1,179 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,156 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.11 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,486.80 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,171.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $776.32 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $591.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lucid Diagnostics INC. | $257.57 | 2023-2024 | |
| Glaxosmithkline, LLC. | $256.02 | 2019-2024 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $227.52 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $225.25 | 2019-2023 | |
| Amgen INC. | $214.39 | 2019-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $190.40 | 2019-2020 | |
| Exact Sciences Corporation | $161.86 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $158.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $121.52 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $108.72 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.17 | 2022-2025 | Caplyta |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Aref listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.